Advanced Biomed Inc. Amends S-1 Registration

Ticker: ADVB · Form: S-1/A · Filed: Oct 28, 2024 · CIK: 1941029

Advanced Biomed INC. S-1/A Filing Summary
FieldDetail
CompanyAdvanced Biomed INC. (ADVB)
Form TypeS-1/A
Filed DateOct 28, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.001, $4.00, $6.00
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, registration, amendment

TL;DR

Advanced Biomed Inc. filed an S-1/A amendment, signaling potential stock registration and future offerings.

AI Summary

Advanced Biomed Inc. filed an S-1/A amendment on October 28, 2024, for its registration statement under the Securities Act of 1933. The company, incorporated in Nevada, has its principal executive offices located at 689-87 Xiaodong Road, Yongkang District, Tainan, Taiwan. This filing is an amendment to a previous registration, indicating ongoing efforts to register securities.

Why It Matters

This S-1/A filing is a step in Advanced Biomed Inc.'s process to register securities, which could lead to a public offering or other capital-raising activities.

Risk Assessment

Risk Level: medium — S-1/A filings are typically associated with companies seeking to raise capital through public offerings, which inherently carry market and execution risks.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this S-1/A filing?

This is an amendment (Amendment No. 13) to a Form S-1 Registration Statement, indicating ongoing updates or revisions to the company's initial filing for securities registration.

When was this amendment filed?

The amendment was filed with the SEC on October 28, 2024.

Where are Advanced Biomed Inc.'s principal executive offices located?

The principal executive offices are located at 689-87 Xiaodong Road, Yongkang District, Tainan, Taiwan.

Who is the agent for service for Advanced Biomed Inc. in New York?

Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168, is the agent for service.

What is the company's state of incorporation?

Advanced Biomed Inc. is incorporated in Nevada.

Filing Stats: 4,527 words · 18 min read · ~15 pages · Grade level 18 · Accepted 2024-10-28 15:56:21

Key Financial Figures

Filing Documents

From the Filing

As filed with the United States Securities and Exchange Commission on October 28, 2024. Registration No. 333-272110 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 13 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Advanced Biomed Inc. (Exact name of registrant as specified in its charter) Nevada 8071 87-2177170 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 689-87 Xiaodong Road, Yongkang District Tainan, Taiwan Tel: 886-6-3121716 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) Cogency Global Inc. 122 East 42nd Street, 18th Floor New York, NY 10168 (212) 947-7200 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies of all communications to: Fang Liu, Esq. VCL Law LLP William S. Rosenstadt, Esq. Mengyi “Jason” Ye, Esq. 1945 Old Gallows Road Ortoli Rosenstadt LLP Suite 260 366 Madison Avenue, 3rd Floor Vienna, VA 22182 New York, NY 10017 Telephone: (703) 919-7285 Telephone: (212) 588-0022 Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box: If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. Large Accelerated Filer Accelerated Filer Non-Accelerated Filer Smaller Reporting Company Emerging Growth Company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall hereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the United States Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine. EXPLANATORY NOTE This Registration Statement contains two prospectuses, as set forth below. Public Offering Prospectus. A prospectus to be used for the public offering of 1,875,000 Common Stock of the Registrant (the “Public Offering Prospectus”) through the underwriter named on the cover page of the Public Offering Prospectus. Resale Prospectus. A prospectus to be used for the resale by the Selling Shareholders of up to 1,875,000 Common Stock of the Registrant (the “Resale Prospectus”). The Resale Prospectus is substantively identical to the Public Offering Prospectus, except for the following principal points: they contain different outside and inside front covers and back covers; the Offering section in the Prospectus Summary section from the Public Offering Prospectus on page 12 is deleted and replaced with a revised the Offering section on page Alt-1; the Use of Proceeds section from the Public Offering Prospectus on page 47 is deleted and replaced with a revised the Use of Proceeds section on page Alt-5; a Selling Shareholder section is included in the Resale Prospectus on page Alt-2; the Underwriting section from the Public Offering Prospectus on page 106 is deleted and replaced with a Selling Shareholders Plan of Distribution section on page Alt-3; and the Legal Matters section from the Public Offering Prospectus on page 114 is deleted and replaced with a revised the L

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing